This is an early-stage pipeline event with no approval timeline or revenue guidance. Monitor for FDA acceptance of the ANDA, patent challenge updates, and any subsequent partnership or financing announcements. No immediate trading catalyst without further regulatory clarity.
Price Chart
Executive Summary
Elite Pharmaceuticals announced it filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant drug. The branded product has $26 billion in trailing twelve-month sales (IQVIA data) with no generic currently on the market, but the brand has unexpired patents and exclusivities that must be addressed before approval. This is an early-stage regulatory milestone with no guaranteed approval timeline or commercial outcome.
Key Facts
- Elite filed an ANDA for a generic version of an undisclosed anticoagulant drug
- Branded product sales were $26 billion for the twelve months ending March 2026 per IQVIA
- No generic product is currently on the market for this drug
- The brand has unexpired patents and exclusivities listed in the FDA Orange Book
- FDA approval and commercialization depend on successful filing, FDA approval, and addressing patents/exclusivities
Financial Impact
No financial figures provided beyond the $26 billion branded market size; Elite's revenue, costs, and potential market share are not disclosed
Risk Factors
- FDA may not accept or approve the ANDA
- Unexpired brand patents and exclusivities could block launch for years or require costly litigation
- Elite may need additional capital to fund development and commercialization
- Generic anticoagulant market may face pricing pressure and competition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026519 |
| Exhibit: ex99-1.htm | 0001493152-26-026519 |
| Document: 0001493152-26-026519-index-headers.html | 0001493152-26-026519 |
| Document: 0001493152-26-026519-index.html | 0001493152-26-026519 |
| Document: 0001493152-26-026519.txt | 0001493152-26-026519 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 10w ago | 8-K | $0.3600 | awaiting T+60 | — | $0.2371 (−34.14%) |
Jun 29, 2026 16w ago | 8-K | $0.3700 $0.2470 | ▼ −33.24% | ▼ −37.08% | $0.2371 (−35.92%) |
Jun 15, 2026 19w ago | 8-K | $0.3700 $0.2599 | ▼ −29.76% | ▼ −31.02% | $0.2371 (−35.92%) |
Jun 1, 2026 21w ago | 8-K | $0.3600 $0.2827 | ▼ −21.47% | ▼ −22.70% | $0.2371 (−34.14%) |
Apr 2, 2026 29w ago | 8-K | $0.3800 $0.3651 | ▼ −3.92% | ▼ −18.08% | $0.2371 (−37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers